Dear colleagues,
First of all, thank you for your continued efforts and dedication to the TELSTAR-2 trial! Your commitment is vital to the success of the trial and highly appreciated!
Important reminders
- Please continue to keep a screening log. For every patient with RPPs who is not included, clarify the reason for non-inclusion. This information is crucial for the quality of our data and future analyses.
- Enrolment of in-hospital cardiac arrest is allowed, this will soon be formalized through a protocol amendment.
- For the Dutch centres: in case you are not yet part of our Siilo group, please let us know!
- For Belgian centres: an email was recently sent to download Siilo on your smartphone so we can create the group.
- Our next plenary investigator meeting is scheduled Wednesday January the 14th at 4PM. If you haven’t received a Teams invite, please let us know!
Resources available
- The protocol, treatment guidelines, and frequently asked questions are always accessible via the trial website: https://telstartrial.nl/
- The rationale for recommended doses of conventional anti-seizure medications and sedative agents for treatment of SE is now available on our website, on the FAQ page.
- As a reminder, instructions for randomization in Research Manager can be found on our website (https://telstartrial.nl/randomization/).
Current status
- 16 centres are actively screening patients.
- 7 patients have been included so far – a promising start thanks to the teams in Radboudumc, Amsterdam UMC, Antonius Ziekenhuis, Catharina Ziekenhuis, Rijnstate, and CHU Sart-Tilman!
Once again, thank you for your valuable contributions. Together, we are making great progress in advancing our knowledge and patient care.